Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Oramed Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th



Oramed Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com
                               on February 7th

Company invites Main Street and Wall Street investors to attend interactive
real-time virtual conference

PR Newswire

NEW YORK, Feb. 5, 2013

NEW YORK, Feb. 5, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTC:ORMPD)
(http://www.oramed.com), a developer of oral drug delivery systems, announced
today that Nadav Kidron, Chief Executive Officer & Director, will present at
RetailInvestorConferences.com.

DATE:     February 7, 2013

TIME:      9:15 AM EST

LINK:      www.retailinvestorconferences.com > red "register / watch event
now" button

This will be a live, interactive online event where investors are invited to
ask the company questions in real-time - both in the presentation hall as well
as the company's "virtual trade booth." If attendees are not able to join the
event live on the day of the conference, an on-demand archive will be
available for 90 days.

It is recommended that investors pre-register to save time and receive event
updates.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's technology is based on over 30 years of research
by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its proprietary
flagship product, an orally ingestible insulin capsule (ORMD-0801) currently
approaching FDA-approved Phase 2 clinical trials, and with its oral exenatide
capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 1b/2a trials.
The company's corporate and R&D headquarters are based in Jerusalem.

About RetailInvestorConferences.com

Since 2010, RetailInvestorConferences.com, created by BetterInvesting (NAIC)
PR Newswire and MUNCmedia, has been the only monthly virtual investor
conference series that provides an interactive forum for presenting companies
to meet directly with retail investors using a graphically-enhanced online
platform.

Designed to replicate the look and feel of location-based investor
conferences, Retail Investor Conferences unites PR Newswire's leading-edge
online conferencing and investor communications capabilities with
BetterInvesting's extensive retail investor audience network and MUNCmedia's
sophisticated retail investor targeting.

SOURCE Oramed Pharmaceuticals Inc.

Website: http://www.oramed.com
Contact: Oramed Pharmaceuticals, Aviva Sherman, aviva@oramed.com,
+972-2-566-0001; or RetailInvestorConferences.com, Bradley H. Smith,
bradley.smith@prnewswire.com, +1-201-942-7157
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement